BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication
BioSpace
After being hit by safety issues and subpar results in another trial, BioMarin's Phase 3 test of Voxzogo for a rare skeletal disorder called hypochondroplasia showed efficacy "solidly above" what the
pharminent
May 21, 2026 (Last updated: May 21, 2026)
BioSpace
After being hit by safety issues and subpar results in another trial, BioMarin’s Phase 3 test of Voxzogo for a rare skeletal disorder called hypochondroplasia showed efficacy “solidly above” what the
